Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046179969> ?p ?o ?g. }
- W2046179969 endingPage "376" @default.
- W2046179969 startingPage "367" @default.
- W2046179969 abstract "In patients with severe asthma, tiotropium improves lung function and exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting β2 agonists. We aimed to assess the safety and efficacy of tiotropium in patients with moderate asthma who were symptomatic despite treatment with medium-dose inhaled corticosteroids.We did two 24-week, replicate, randomised, double-blind, placebo-controlled, parallel-group, active-comparator trials at 233 sites in 14 countries. Eligible patients were aged 18-75 years with symptomatic asthma and a pre-bronchodilator forced expiratory volume in 1 s (FEV1) of 60-90% predicted despite use of medium-dose inhaled corticosteroids, and had never smoked or were ex-smokers for 1 year or more with 10 pack-years or less. Patients were randomly assigned (1:1:1:1), with computer-generated pseudorandom numbers, to receive once-daily tiotropium 5 μg or 2·5 μg, twice-daily salmeterol 50 μg, or placebo, while maintaining inhaled corticosteroids. Patients and study investigators were masked to treatment allocation. Prespecified co-primary endpoints, assessed at week 24 in the full analysis set, were peak FEV1 response, measured within the first 3 h after evening dosing; trough FEV1 response; and responder rate assessed according to the seven-question Asthma Control Questionnaire (ACQ-7). These studies are registered with ClinicalTrials.gov, numbers NCT01172808 and NCT01172821.Between Aug 24, 2010, and Nov 13, 2012, we randomly assigned 2103 patients to the tiotropium 5 μg group (n=519), the tiotropium 2·5 μg group (n=520), the salmeterol group (n=541), or the placebo group (n=523); 1972 (94%) patients completed the study. Peak and trough FEV1 responses were significantly greater with tiotropium and salmeterol than with placebo and were similar in both studies. With pooled data, difference versus placebo in peak FEV1 was 185 mL (95% CI 146-223) in the tiotropium 5 μg group, 223 mL (185-262) in the tiotropium 2·5 μg group, and 196 mL (158-234) in the salmeterol group (all p<0·0001); difference in trough FEV1 was 146 mL (95% CI 105-188), 180 mL (138-221), and 114 mL (73-155; all p<0·0001), respectively. There were more ACQ-7 responders in the tiotropium 5 μg (OR 1·32, 95% CI 1·02-1·71; p=0·035) and 2·5 μg (1·33, 1·03-1·72; p=0·031) groups, and the salmeterol group (1·46, 1·13-1·89; p=0·0039), than in the placebo group. 48 (2%) of 2100 patients had serious adverse events (tiotropium 5 μg n=11, tiotropium 2·5 μg n=12, salmeterol n=11, placebo n=14).Once-daily tiotropium add-on to medium-dose inhaled corticosteroids reduces airflow obstruction and improves asthma control in patients with moderate symptomatic asthma. Patterns of response with both tiotropium doses were similar to those of salmeterol, and all active compounds had good safety and tolerability. Tiotropium is a safe and effective bronchodilator, and an alternative to salmeterol in this patient population.Boehringer Ingelheim." @default.
- W2046179969 created "2016-06-24" @default.
- W2046179969 creator A5013428765 @default.
- W2046179969 creator A5022845882 @default.
- W2046179969 creator A5027731238 @default.
- W2046179969 creator A5033206232 @default.
- W2046179969 creator A5043194272 @default.
- W2046179969 creator A5043284155 @default.
- W2046179969 creator A5048656238 @default.
- W2046179969 creator A5069959810 @default.
- W2046179969 creator A5088182623 @default.
- W2046179969 creator A5088842944 @default.
- W2046179969 creator A5090062530 @default.
- W2046179969 date "2015-05-01" @default.
- W2046179969 modified "2023-10-01" @default.
- W2046179969 title "Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials" @default.
- W2046179969 cites W128731631 @default.
- W2046179969 cites W1910738679 @default.
- W2046179969 cites W1972813104 @default.
- W2046179969 cites W2009191674 @default.
- W2046179969 cites W2027285152 @default.
- W2046179969 cites W2030556594 @default.
- W2046179969 cites W2031245994 @default.
- W2046179969 cites W2056770521 @default.
- W2046179969 cites W2063045365 @default.
- W2046179969 cites W2096723137 @default.
- W2046179969 cites W2108715624 @default.
- W2046179969 cites W2111609315 @default.
- W2046179969 cites W2113934803 @default.
- W2046179969 cites W2117993701 @default.
- W2046179969 cites W2119147796 @default.
- W2046179969 cites W2123820104 @default.
- W2046179969 cites W2126325768 @default.
- W2046179969 cites W2141034778 @default.
- W2046179969 cites W2148583736 @default.
- W2046179969 cites W2150634254 @default.
- W2046179969 cites W2162154826 @default.
- W2046179969 cites W2168922709 @default.
- W2046179969 cites W2171331726 @default.
- W2046179969 cites W2601675613 @default.
- W2046179969 doi "https://doi.org/10.1016/s2213-2600(15)00031-4" @default.
- W2046179969 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25682232" @default.
- W2046179969 hasPublicationYear "2015" @default.
- W2046179969 type Work @default.
- W2046179969 sameAs 2046179969 @default.
- W2046179969 citedByCount "154" @default.
- W2046179969 countsByYear W20461799692015 @default.
- W2046179969 countsByYear W20461799692016 @default.
- W2046179969 countsByYear W20461799692017 @default.
- W2046179969 countsByYear W20461799692018 @default.
- W2046179969 countsByYear W20461799692019 @default.
- W2046179969 countsByYear W20461799692020 @default.
- W2046179969 countsByYear W20461799692021 @default.
- W2046179969 countsByYear W20461799692022 @default.
- W2046179969 countsByYear W20461799692023 @default.
- W2046179969 crossrefType "journal-article" @default.
- W2046179969 hasAuthorship W2046179969A5013428765 @default.
- W2046179969 hasAuthorship W2046179969A5022845882 @default.
- W2046179969 hasAuthorship W2046179969A5027731238 @default.
- W2046179969 hasAuthorship W2046179969A5033206232 @default.
- W2046179969 hasAuthorship W2046179969A5043194272 @default.
- W2046179969 hasAuthorship W2046179969A5043284155 @default.
- W2046179969 hasAuthorship W2046179969A5048656238 @default.
- W2046179969 hasAuthorship W2046179969A5069959810 @default.
- W2046179969 hasAuthorship W2046179969A5088182623 @default.
- W2046179969 hasAuthorship W2046179969A5088842944 @default.
- W2046179969 hasAuthorship W2046179969A5090062530 @default.
- W2046179969 hasConcept C121332964 @default.
- W2046179969 hasConcept C126322002 @default.
- W2046179969 hasConcept C1276947 @default.
- W2046179969 hasConcept C142724271 @default.
- W2046179969 hasConcept C168563851 @default.
- W2046179969 hasConcept C204787440 @default.
- W2046179969 hasConcept C27081682 @default.
- W2046179969 hasConcept C2776042228 @default.
- W2046179969 hasConcept C2776476923 @default.
- W2046179969 hasConcept C2776719499 @default.
- W2046179969 hasConcept C2776804153 @default.
- W2046179969 hasConcept C2776968687 @default.
- W2046179969 hasConcept C2777014857 @default.
- W2046179969 hasConcept C2777714996 @default.
- W2046179969 hasConcept C2781018748 @default.
- W2046179969 hasConcept C2991922776 @default.
- W2046179969 hasConcept C3018587741 @default.
- W2046179969 hasConcept C42219234 @default.
- W2046179969 hasConcept C71924100 @default.
- W2046179969 hasConceptScore W2046179969C121332964 @default.
- W2046179969 hasConceptScore W2046179969C126322002 @default.
- W2046179969 hasConceptScore W2046179969C1276947 @default.
- W2046179969 hasConceptScore W2046179969C142724271 @default.
- W2046179969 hasConceptScore W2046179969C168563851 @default.
- W2046179969 hasConceptScore W2046179969C204787440 @default.
- W2046179969 hasConceptScore W2046179969C27081682 @default.
- W2046179969 hasConceptScore W2046179969C2776042228 @default.
- W2046179969 hasConceptScore W2046179969C2776476923 @default.
- W2046179969 hasConceptScore W2046179969C2776719499 @default.
- W2046179969 hasConceptScore W2046179969C2776804153 @default.
- W2046179969 hasConceptScore W2046179969C2776968687 @default.